Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance - ATRIPLA®
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (NASDAQ: GILD) today announced an agreement to commercialize ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe for the treatment of virologically suppressed adults with HIV-1 infection, subject to the product's approval by the European Commission.
AstraZeneca Files Patent Infringement Actions in Response to Crestor⢠ANDAs
- Details
- Category: AstraZeneca
AstraZeneca announced that it has filed patent infringement actions in United States District Court, District of Delaware, against seven generic drug manufacturers, which have submitted Abbreviated New Drug Applications (ANDAs) for Crestor™.
Pharmion and MethylGene Present Favorable Clinical Data
- Details
- Category: Clinical Trials
Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc (TSX: MYG) announced maturing data from the Phase 1/2 study investigating the combined use of MGCD0103, a novel, isotype-selective histone deacetylase (HDAC) inhibitor, and Vidaza(R) (azacitidine for injection) in patients with myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML).
GlaxoSmithKline and OncoMed Pharmaceuticals form strategic alliance
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and OncoMed Pharmaceuticals (OncoMed) today announced a worldwide strategic alliance to discover, develop and market novel antibody therapeutics to target cancer stem cells which are believed to play a key role in the establishment, metastasis and recurrence of cancer. The alliance with GSK will be conducted through its Center of Excellencefor External Drug Discovery (CEEDD).
Pivotal Phase III Data Show Superior Efficacy of Rivaroxaban over Enoxaparin
- Details
- Category: Bayer
The oral, once-daily, investigational anticoagulant rivaroxaban (Xarelto®) is significantly more effective than enoxaparin, the standard of care, in preventing venous thromboembolism (VTE) in patients undergoing total hip replacement surgery. Data from the RECORD1 study show a 70% relative risk reduction (RRR) for rivaroxaban in total VTE when compared with enoxaparin (p<0.001) and an 88% RRR (p<0.001) in major VTE.
GSK's continued commitment to fighting HIV/AIDS results in approval of new formulations
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it had gained approval from the European Commission for a new indication for use in children and infants of its HIV fixed-dose combination medicine, Combivir (lamivudine/3TC and Zidovudine/AZT). Previously, Combivir has only been prescribed for use in adults and children over 12 years of age, the shift to new weight based prescribing will allow Combivir to be used in much younger children.
Pfizer and Adolor Enter into Exclusive Worldwide Collaboration
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) and Adolor Corporation (Nasdaq: ADLR) announced today an exclusive worldwide collaboration to develop and commercialize novel compounds, ADL5859 and ADL5747, for the treatment of pain. Both compounds are proprietary Delta opioid receptor agonist candidates with the potential to treat a wide range of inflammatory, neuropathic and acute pain conditions.
More Pharma News ...
- Merz Group experiences successful 2006/07 financial year
- AstraZeneca Presents New Depression and Anxiety Results for SEROQUEL XRâ¢
- Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
- Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration
- Bayer Schering Pharma paves the way to the next important oral contraceptive milestone
- FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
- GlaxoSmithKline obtains exclusive US OTC marketing rights to Mevacor® from Merck & Co., Inc.